SeaSpine to Report Second Quarter 2020 Financial Results on August 4, 2020

Rhea-AI Summary

SeaSpine Holdings Corporation (NASDAQ: SPNE) will announce its second quarter financial results on August 4, 2020, after market close. A conference call will follow at 2:30 PM PT / 5:30 PM ET, where management will discuss the results. Interested parties can join the call by dialing (877) 418-4766 for domestic calls or (614) 385-1253 for international access, using Conference ID: 2209758. SeaSpine specializes in surgical solutions for spinal disorders, offering a broad range of orthobiologics and spinal implants globally.

Positive

• Upcoming financial results on August 4, 2020, may show growth or recovery indicators.
• Broad portfolio of orthobiologics and spinal implants enhances market competitiveness.

Negative

• None.

CARLSBAD, Calif., July 22, 2020 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release second quarter financial results after the close of trading on Tuesday, August 4, 2020. Members of the Company’s management will host a corresponding conference call and webcast beginning at 2:30 pm PT / 5:30 pm ET.

Individuals interested in listening to the conference call may do so by dialing (877) 418-4766 for domestic callers or (614) 385-1253 for international callers, using Conference ID: 2209758. To listen to a live webcast, please visit the Investors section of the SeaSpine website at: www.seaspine.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in both orthobiologic sciences and spinal implants product development allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Relations Contact   
Leigh Salvo
(415) 937-5402
ir@seaspine.com 

FAQ

When will SeaSpine release its second quarter financial results?

SeaSpine will release its second quarter financial results on August 4, 2020.

What time is the SeaSpine conference call scheduled?

The conference call is scheduled for 2:30 PM PT / 5:30 PM ET on August 4, 2020.

How can I listen to the SeaSpine conference call?

You can listen to the conference call by calling (877) 418-4766 for domestic and (614) 385-1253 for international access, using Conference ID: 2209758.

What is SeaSpine's focus as a medical technology company?

SeaSpine focuses on surgical solutions for spinal disorders, offering a range of orthobiologics and spinal implants.